KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EBIT: 2019-2025

Historic EBIT for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $427.2 million.

  • Royalty Pharma's EBIT fell 41.89% to $427.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 0.72%. This contributed to the annual value of $1.3 billion for FY2024, which is 13.38% down from last year.
  • As of Q3 2025, Royalty Pharma's EBIT stood at $427.2 million, which was up 103.60% from $209.8 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's EBIT registered a high of $744.9 million during Q2 2021, and its lowest value of -$482.7 million during Q4 2022.
  • Its 3-year average for EBIT is $359.6 million, with a median of $361.5 million in 2024.
  • As far as peak fluctuations go, Royalty Pharma's EBIT plummeted by 414.60% in 2022, and later soared by 824.08% in 2025.
  • Quarterly analysis of 5 years shows Royalty Pharma's EBIT stood at $153.4 million in 2021, then crashed by 414.60% to -$482.7 million in 2022, then spiked by 226.98% to $612.9 million in 2023, then slumped by 41.02% to $361.5 million in 2024, then crashed by 41.89% to $427.2 million in 2025.
  • Its EBIT was $427.2 million in Q3 2025, compared to $209.8 million in Q2 2025 and $534.2 million in Q1 2025.